{"contentid": 488472, "importid": NaN, "name": "Pyxis unveils ambitions on ADCs", "introduction": "Privately-held Pyxis Oncology has announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional details and preclinical data supporting the potential of its ADC platform.", "content": "<p>Privately-held Pyxis Oncology has announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional details and preclinical data supporting the potential of its ADC platform.</p>\n<p>The US company expects to progress the candidates to investigational new drug (IND) submissions next year.</p>\n<p><span class=\"pullQuote\">\"We believe our ADCs may apply to a broad patient population as single agents and in combination with immunotherapies to further improve the outcome for patients with difficult-to-treat cancers\"</span>They are PYX-201, a first-in-class non-internalizing ADC that targets extra domain-B (EDB) of fibronectin.</p>\n<p>EDB is an oncofetal splice variant of fibronectin, a key component of the tumor extracellular matrix that is highly expressed across several solid tumors, including non-small cell lung cancer, ovarian, breast and pancreatic cancers.</p>\n<p>PYX-201 is designed to release an auristatin payload with bystander activity into the extracellular space to induce immunogenic cell death to kill tumor cells and their supporting infrastructure.</p>\n<p>Then there is PYX-202, an internalizing ADC targeting delta-like 1 homolog, a tumor antigen that is restricted in normal tissues but expressed in a range of solid tumors, including small cell lung cancer, soft tissue sarcoma, hepatocellular carcinoma and neuroblastoma.</p>\n<p>PYX-202 uses a well-understood toxic agent, monomethyl auristatin payload and a beta-glucuronide cleavable linker designed to increase stability in circulation and reduce off-target toxicities.</p>\n<p>Another candidate is PYX-203, an internalizing ADC targeting CD123, a clinically-validated target primarily expressed in several high need hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and others.</p>\n<p>PYX-203 utilizes a lysosomal cleavable linker and a highly potent cyclopropylpyrroloindole DNA-damaging payload that may reduce the drug concentration needed to achieve positive treatment outcomes while limiting unwanted side effects.</p>\n<p>A larger patient population may benefit from PYX-203, including patients who otherwise would not respond to the standard of care, according to Pyxis.</p>\n<p>Ronald Herbst, chief scientific officer of Pyxis, said: &ldquo;ADCs represent a promising therapeutic modality, but historically their advancement has been limited due to on and off-target toxicities.</p>\n<p>&ldquo;Our ADC assets have been specifically designed and developed using site-specific conjugation chemistry to combine new and established targets, linkers and payloads. All three candidates are potent with highly stable linker-payload conjugation &ndash; characteristics that have led to superior therapeutic indexes. We believe our ADCs may apply to a broad patient population as single agents and in combination with immunotherapies to further improve the outcome for patients with difficult-to-treat cancers.&rdquo;</p>", "date": "2021-04-27 16:54:00", "meta_title": NaN, "meta_keywords": NaN, "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-27 16:47:50", "updated": "2021-04-27 18:43:37", "access": NaN, "url": "https://www.thepharmaletter.com/article/pyxis-unveils-ambitions-on-adcs", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "pyxis_oncology_large.png", "image2id": "pyxis_oncology_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "One to Watch Companies, Research", "geography_tag": "USA", "company_tag": "Pyxis Oncology", "drug_tag": "PYX-201, PYX-203", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-27 16:54:00"}